Effect of Batimastat on Colorectal Cancer
Author Information
Author(s): SA Watson, TM Morris, SL Parsons, RJC Steele, PD Brown
Primary Institution: Cancer Studies Unit, Department of Surgery, Queen's Medical Centre, Nottingham
Hypothesis
Can the matrix metalloproteinase inhibitor batimastat reduce ascites and solid tumor growth in a colorectal cancer model?
Conclusion
Batimastat significantly reduced ascites volume and solid tumor deposits in a colorectal cancer model when administered from the start of treatment.
Supporting Evidence
- Batimastat reduced ascites volume to 21% of control when administered from day 0.
- Solid tumor deposits were reduced to 77% of control with batimastat from day 0.
- Treatment from day 10 did not significantly affect ascites volume.
Takeaway
Batimastat is a medicine that helps shrink tumors and reduce fluid buildup in the belly for mice with colon cancer.
Methodology
The study used SCID mice injected with a human colorectal cancer cell line and treated with batimastat to assess its effects on ascites and tumor growth.
Limitations
The study was conducted in mice, which may not fully represent human responses.
Participant Demographics
60 female SCID mice, aged 6-10 weeks.
Statistical Information
P-Value
<0.002
Statistical Significance
p<0.002
Want to read the original?
Access the complete publication on the publisher's website